← Back to all trials
Not Yet Recruiting
NCT05669001
A Study of TCD601 in de Novo Renal Transplant Recipients
Conditions: Renal Transplantation
Sex: All
Ages: 18 Years – 70 Years
Phase: PHASE2
Enrollment: 90
Sponsor: ITB-Med LLC
Summary
The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.
Eligibility Criteria
Key Inclusion Criteria:Able to understand the study requirements and provide written informed consent before and study assessment is performedMale or female patients ≥ 18 to 70 years of ageRecipients of a de novo renal allograft from a heart-beating deceased, living ABO compatable, non-HLA identical living related donorKey Exclusion Criteria:Subjects who have received a kidney allograft previouslyRecipient of a kidney from an HLA identical living related donorRecipient of a kidney from a donor after cardiac death
Source: ClinicalTrials.gov (NCT05669001). StuddyBuddy aggregates publicly available trial information.
